5Watson AJ, Hart AR. Environmental risk factors for inflammatory bowel disease: microbes, diet, and the appendix [J]. Gastroenterology,2011,141(2):768-770.
6Barclay AR,Russell RK,Wilson ML,et al. Systematic review: the role of breast feeding in the development of pediatric inflammatory bowel disease[J]. J Pediatr, 2009,155 (3) : 421- 426.
7Persad R,Jaffer I,Issenman RM. The prevalence of long bone fractures in pediatric inflammatory bowel disease[J]. J Pediatr Gastroenterol Nutr,2006,43(5) :597-602.
8Vermeire S,van Assche G,Rutgeerts P. Laboratory markers in IBD: useful, magic, or unnecessary toys[J]. Gut, 2006,55 (3) 426-431.
9Austin GL, Shaheen NJ, Sandier RS. Positive and negative predictive values: use of inflammatory bowel disease serologic markers[J]. Am J Gastroenterol, 2006,101 (3) : 413-416.
7Loftus CG, Loftus EV Jr, Harmsen WS, et al. Update on the incidence and prevalence of Crohn's disease and ulcecative colitis in Olmsted County, Minnesota, 1940-2000. Inflamm Bowel Dis, 2007, 13:2,54-261.
8Zheng JJ, Zhu XS, Huangfu Z, et al. Crohn's disease n China's Mainland: a systematic analysis of 50 years research. Chin J Dig Dis, 2005, 6:175-181.
9Hanauer SB, Fragan BG, Liehtenstein GR, et al. Maintenance infliximab for Crohn's disease: the ACCENT I randomized trial. Lancet, 2002, 359 : 15410-1549.
10Lichtenstein GR, Yan S, Bala M, et al.Infliximab maintenance treatment reduces hospitalizatins surgeries, and procedures in fistulizing Crohn's disease. Gastroenterology, 2005, 128:862-869.
